Tag: femoropopliteal

REALITY study “sets new benchmark” for assessment of claudicants with severe...

Krishna Rocha-Singh (Springfield, USA) speaks to Vascular News about his presentation at VIVA20 (Vascular Interventional Advances; 6–7 November 2020; virtual) on the REALITY study,...

Veryan Medical announces US launch and first commercial implant of BioMimics...

Veryan Medical recently announced the US launch and first commercial implant in the USA of the BioMimics 3D vascular stent system. According to a press...

Customising therapy in femoropopliteal revascularisation

 Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based therapies have become a mainstay in femoropopliteal revascularisation and how interventionalists...

New JAMA analysis with short follow-up finds “an association of survival”...

A recent US-wide, multicentre analysis has found no evidence of increased all-cause mortality associated with the use of paclitaxel-coated devices compared with non-drug-coated devices...

Patient-level survival analysis demonstrates no link between paclitaxel dose and mortality...

New data on the IN.PACT Admiral drug-coated balloon (DCB; Medtronic) in patients with peripheral arterial disease (PAD) in the superficial femoral (SFA) and popliteal...

IN.PACT independent patient-level meta-analysis shows no correlation between paclitaxel exposure and...

 A renowned panel, moderated by Dierk Scheinert (Leipzig, Germany), comprising Peter Schneider (Honolulu, USA), John Laird (St Helena, USA) and Thomas Zeller (Bad Krozingen,...